Simulations Plus (NASDAQ:SLP): Promising Potential in Biotech Software
TipRanks (Tue, 16-Apr 5:48 AM ET)
U.S. FDA Renews DILIsym Software Licenses for 7th Year
Business Wire (Thu, 4-Apr 8:30 AM ET)
Simulations Plus Reports Second Quarter Fiscal 2024 Financial Results
Business Wire (Wed, 3-Apr 4:34 PM ET)
Simulations Plus Announces Second Quarter Fiscal Year 2024 Earnings and Conference Call Date
Business Wire (Wed, 20-Mar 4:06 PM ET)
Business Wire (Wed, 13-Mar 8:30 AM ET)
Simulations Plus and the University of Bath Awarded New FDA Grant
Business Wire (Tue, 5-Mar 8:30 AM ET)
Simulations Plus Extends Collaboration with Major Toxicology Research Agency
Business Wire (Thu, 15-Feb 8:30 AM ET)
Simulations Plus Launches Corporate Development Initiative
Business Wire (Tue, 13-Feb 9:15 AM ET)
Simulations Plus to Participate in Upcoming Healthcare Conferences
Business Wire (Tue, 6-Feb 8:30 AM ET)
Simulations Plus Releases GastroPlus Version 9.9
Business Wire (Tue, 30-Jan 8:30 AM ET)
Simulations Plus Inc is engaged in the software industry. It develops and produces software for use in pharmaceutical research and education, and provides consulting and contract research services to the pharmaceutical industry. The company's operating segments include Software and services. It generates maximum revenue from the software segment.
Simulations Plus trades on the NASDAQ stock market under the symbol SLP.
As of April 17, 2024, SLP stock price declined to $44.70 with 79,542 million shares trading.
SLP has a beta of 1.43, meaning it tends to be more sensitive to market movements. SLP has a correlation of 0.17 to the broad based SPY ETF.
SLP has a market cap of $892.48 million. This is considered a Small Cap stock.
Last quarter Simulations Plus reported $18 million in Revenue and $.20 earnings per share. This beat revenue expectation by $1 million and exceeded earnings estimates by $.01.
In the last 3 years, SLP stock traded as high as $70.50 and as low as $32.58.
The top ETF exchange traded funds that SLP belongs to (by Net Assets): IJR, VTI, IWM, VXF, SPSM.
SLP stock has underperformed the market in the last year with a return of +2.9%, while SPY returned +23.0%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in SLP shares. However, SLP has outperformed the market in the last 3 month and 2 week periods, returning +17.0% and +15.8%, while SPY returned +5.7% and -3.5%, respectively. This indicates SLP has been having a stronger performance recently.
SLP support price is $44.04 and resistance is $46.68 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that SLP stock will trade within this expected range on the day.